Description

GP100 (209-217) is a 9-aa peptide derived from human gp100 beginning at position 20[1].—Cancer-programmed cell death–C46H72N10O15—-[1]Changes in the fine specificity of gp100209–217-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.–162558-10-3–1005.12—-CC[C@H](C)[C@H](N)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)C)C(N1[C@@H](CCC1)C(N[C@H](C(N[C@@H](CO)C(N[C@H](C(O)=O)C(C)C)=O)=O)CC2=CC=CC=C2)=O)=O)=O)=O)=O)=O–Cancer–10 mM in DMSO–Others—-Others–Peptides